IDDF2024-ABS-0194 Real-world data with pangenotypic direct-acting antivirals: preliminary results of the SVR10K study

Background A previous real-world data analysis demonstrated the high effectiveness of sofosbuvir/velpatasvir (SOF/VEL) in > 6,000 HCV patients from 12 clinical cohorts across Australia, Canada, Europe & USA. Expanding this research initiative to include even more patients from additional geographical areas will allow us to show SOF/VEL effectiveness across multiple diverse populations & the evaluation of HCV patient characteristics across Western countries, Asia, Middle Eastern, and Latin-American regions. Methods This real-world analysis includes patients ≥ 18 years treated with SOF/VEL without RBV for 12 weeks, as decided by the treating HCP, from 7 sites across Hong Kong, Mexico, Sweden, Spain, Taiwan, and the United Arab Emirates. Age, sex, treatment-experienced (TE), cirrhosis stage (no decompensated included), genotype, coinfections, time to treatment initiation (TTI) from HCV diagnosis, and SVR (4/12/24) were analyzed. Results Overall, 4,679 patients were included, 51% of them from Asian countries. Median age was 56.9 [IQR 46-66], where males were 59%, and age > 50 years in 68%. Genotype 3 was present in 25%, F4 21%, TE 5%, while HIV, HBV and HDV coinfection was reported in 4.7%, 4.3%, and 0.1%, respectively. The TTI was available in 74%, with 17% having ≤30 days. In terms of effectiveness, SVR was achieved in 98.4% of the treated population and 99% of Asian countries. Conclusions Results on treatment effectiveness in these new geographies did not differ from real-world studies of patients in Western countries, reinforcing that HCV treatment guidelines are globally applicable and supporting the efficacy of pDAA therapy.